IgM promotes antitumor immunity to a Tn-expressing solid tumor Authors: Hope L Nzuki, Jamie E Jennings-Gee, Michaela Trivette, Timothy H Mosher, Alexis E Adams-Sims, Abigail A Hegarty, Karen M Haas Published: 2026 ABSTRACT AbstractBackgroundAltered O-glycosylation is a hallmark of many adenocarcinomas and is often characterized by expression of the Tn antigen. However, the role of B cells in protection against Tn-expressing solid tumors remains poorly understood.MethodsWe generated a colorectal tumor cell line (CMT93) lacking Cosmc, resulting in high Tn expression. Using mice with defined B-cell abnormalities, including deficiencies in B cells, IgM secretion, natural IgM, and B-cell receptor (BCR) repertoire diversity, we investigated the contribution of B cells and secreted antibody to immunity against Tn-expressing colorectal tumors.ResultsCosmc-deficient tumors grew more rapidly than parental tumors, and IgM deposition was observed within tumors from wild-type mice, suggesting a potential role for antibody in antitumor defense. Tumor-reactive serum IgM, including Tn-reactive IgM, was present in naïve mice. B cell-deficient muMT, VHB1-8 transgenic mice with a restricted BCR repertoire, CD19−/− mice deficient in natural IgM, and μS−/− mice unable to secrete IgM, lacked tumor-reactive IgM and showed increased tumor burdens, suggesting a protective role for secreted tumor-reactive IgM. Lack of tumor-reactive IgM in VHB1-8 transgenic and μS−/− mice was associated with significant alterations in tumor-infiltrating leukocyte composition. Relative to wild-type mice, tumors from VHB1-8 transgenic and μS−/− mice exhibited significantly increased PD-L1hiLy6G+Ly6C−CD11b+ myeloid cells, but reduced B, T, and natural killer cells, along with reduced major histocompatibility complex class II expression on tumor-associated dendritic cells. Moreover, tumor draining lymph nodes from VHB1-8 transgenic and μS−/− mice showed significant reductions in antibody-secreting cells, including IgG+ plasmablasts, which corresponded with decreased IgM and IgG deposition on tumors.ConclusionsThese findings support a role for B cells and secreted IgM in restraining the growth of Tn-expressing solid tumors and shaping antitumor immunity against tumors with aberrant O-glycosylation. WHAT IS ALREADY KNOWN ON THIS TOPIC Altered O-linked glycosylation is common in adenocarcinomas and can generate surface-displayed tumor-associated carbohydrate antigens such as Tn, but how B cells and the antibodies they produce influence immunity to Tn-expressing solid tumors remains poorly understood. Altered O-linked glycosylation is common in adenocarcinomas and can generate surface-displayed tumor-associated carbohydrate antigens such as Tn, but how B cells and the antibodies they produce influence immunity to Tn-expressing solid tumors remains poorly understood. WHAT THIS STUDY ADDS This study shows that naïve mice harbor naturally occurring tumor-reactive IgM, including Tn-reactive IgM, and that loss of B cells or their ability to secrete tumor-reactive IgM compromises protection against Tn-bearing tumors. Tumor-reactive IgM deposits on tumors, promotes IgG deposition, and is associated with a more protective tumor microenvironment characterized by reduced immunosuppressive myeloid cells, increased dendritic cell activation, and greater infiltration of B cells, CD4+ T cells, and CD8+ T cells. This study shows that naïve mice harbor naturally occurring tumor-reactive IgM, including Tn-reactive IgM, and that loss of B cells or their ability to secrete tumor-reactive IgM compromises protection against Tn-bearing tumors. Tumor-reactive IgM deposits on tumors, promotes IgG deposition, and is associated with a more protective tumor microenvironment characterized by reduced immunosuppressive myeloid cells, increased dendritic cell activation, and greater infiltration of B cells, CD4+ T cells, and CD8+ T cells. HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY These findings highlight naturally occurring tumor-reactive IgM as an important regulator of protective immunity to aberrantly glycosylated tumors and support further investigation of IgM-dependent mechanisms in antitumor immune surveillance. These findings highlight naturally occurring tumor-reactive IgM as an important regulator of protective immunity to aberrantly glycosylated tumors and support further investigation of IgM-dependent mechanisms in antitumor immune surveillance. Introduction Aberrant glycosylation, a cancer hallmark, influences tumorigenesis, immune evasion, and metastasis. Among the best-studied tumor-associated carbohydrate antigens (TACAs) is Tn (GalNAcα1-O-Ser/Thr), which arises from incomplete O-glycosylation.1 2 Truncated glycans are expressed in up to 90% of human carcinomas and correlate with poor prognosis and metastatic potential.3–6 Tn expression results from mucin overexpression and dysregulated glycosylation, sialylation, and glycosyltransferase activity. Mutations in or epigenetic silencing of Cosmc, a chaperone required for T-synthase folding and O-glycan elongation beyond core GalNAc residues, are often responsible for Tn expression.7 Engineered Tn expression enhances epithelial-mesenchymal transition and metastasis in experimental models, underscoring its role as a driver of aggressive phenotypes.8 9 Immune responses to Tn-bearing glycoproteins, especially mucins, may be difficult to induce due to their self-nature and heavy glycosylation, which poses a challenge for processing and antigen presentation, and hence, inducing T-cell responses.10 Nonetheless, humoral responses to tumor glycans, including TACA-reactive IgM, occur in patients and correlate with improved survival.11 12 Natural IgM binds conserved patterns on altered self-molecules, including tumor-associated glycans and glycolipids, and may facilitate clearance of transformed cells.13 The role of B cells in tumor immunity remains debated due to discordant results using B cell-deficient mice and/or immunosuppressive regulatory B cells.14–16 However, studies across cancer types show that increased tumor-infiltrating B cells predict improved survival, even after metastases.17–19 Our previous work in peritoneal carcinomatosis and leukocytosis models showed that natural IgM and the innate B cells that produce these antibodies in response to toll-like receptor (TLR) activation are indispensable for TLR agonist-based immunotherapy, and support a role for natural IgM in antitumor defense.20 21 In the absence of pathogen associated molecular patterns, natural antibodies are critical for rejection of neoantigen-expressing cells, as shown in allotypic rejection and B16 melanoma mouse models.15 In particular, IgM complexed with neoantigen-expressing cells may license monocytes and, through CD4+ T-cell help, activate cross-presenting dendritic cells (DCs) to initiate cytotoxic T-cell responses.22 To our knowledge, no studies have directly examined whether B cells or secreted IgM influence in vivo solid tumor growth of Tn-positive tumors. Herein, we disrupted Cosmc in CMT93 mouse colorectal cancer cells to generate a line expressing high levels of Tn and investigate tumor growth in vivo. CMT93-Cosmc− cells exhibited increased tumor growth in vivo, which was further augmented in immunodeficient Rag1−/− and B cell-deficient muMT mice. IgM deposition in wild-type (WT) tumors coincided with serum IgM reactivity, a portion of which was Tn-reactive. Growth of CMT93-Cosmc− tumors in mice with B cell and IgM deficits suggests a protective role for B cells related not only to IgM targeting of tumor cells, but also to its capacity to promote adaptive antitumor responses. Results Cosmc-deficient CMT93 cells express high levels of Tn and grow more aggressively in vivo Loss of function mutations in COSMC and high Tn expression are reported in human colorectal and other cancer types.23 To model this, we generated a Cosmc-deficient CMT93 murine colorectal cell line using CRISPR/Cas9, with confirmation by PCR and western blot (see online supplemental figure 1A–D). CMT93-Cosmc− cells exhibit high levels of vicia villosa lectin (VVL) (Tn-specific) binding and negligible levels of peanut agglutinin (PNA) (T antigen-specific) binding relative to Cosmc-expressing parental cells both in vitro (figure 1A) and in vivo (figure 1B). Sialylation of Tn on CMT93-Cosmc− cells was minimal based on B72.3 and VVL staining and the negligible effects of neuraminidase treatment (see online supplemental figure 1E). CMT93-Cosmc− tumors grew more aggressively in immunocompetent WT mice (figure 1C) and immunodeficient Rag1−/− mice (see online supplemental figure 2A) relative to parental CMT93 tumors as indicated by increased tumor volume and mass at harvest, similar to previous reports of aggressive growth by Cosmc-deficient breast and colorectal tumors.8 24 CMT93-Cosmc− cells are VVLhi/PNAlo and grow aggressive tumors in immunocompetent wild-type mice. (A) VVL-fluorescein and PNA-Alexa Fluor 568 staining of CMT93 or CMT93-Cosmc− cells to detect Gal-β1–3-GalNAc (T antigen, PNA) and Tn antigen (VVL) by flow cytometry. No stain controls are indicated by gray shaded histograms. (B) VVL-fluorescein and PNA-Alexa Fluor 568 staining of CMT93 or CMT93-Cosmc− tumor sections, with MFI (±SD) determined using ImageJ software (CMT93, n=2 sections from tumors from two separate mice; CMT93-Cosmc− n=5 tumor sections from five different mice). (C) WT mice were challenged with 4×106 CMT93 or CMT93-Cosmc− cells s.c., with volumes measured every 3 days and masses recorded at harvest (n=9 mice/group). Results representative of two independent tumor challenges. P values are indicated above histograms or represented as asterisks as determined by two-tailed unpaired Student’s t-test (*p<0.05). MFI, mean fluorescence intensity; PNA, peanut agglutinin; s.c., subcutaneously; VVL, vicia villosa lectin; WT, wild-type. Natural IgM reactivity with CMT93-Cosmc− cells includes Tn-reactive IgM Patients who produce TACA-reactive antibodies have improved long-term prognosis.11 12 25 Nonetheless, Tn-expressing colorectal tumors in some patients are immune cold.26 We therefore assessed antibody binding to these tumors by flow cytometry and immunohistochemistry. Relative to B cell-deficient muMT control sera alone or spiked with negative control IgM mAb (monoclonal antibody), sera from naïve WT mice showed significant IgM, but not IgG, binding to CMT93-Cosmc− cells (figure 2A; see online supplemental figure 2B). Notably, serum IgM from naïve WT mice showed significantly greater binding to CMT93-Cosmc− cells than to the parental CMT93 cells (see online supplemental figure 2C). In vivo, we detected IgM deposition in WT tumor sections by immunofluorescence (figure 2B), and flow cytometry of harvested single-cell suspensions of CMT93-Cosmc− tumors showed IgM deposition on VVLhi tumor cells relative to background signals in tumors from muMT mice (figure 2C; see gating strategy in online supplemental figure 2E). It is unclear whether this reflects natural or induced IgM, or both, although we did not find significant increases in CMT93-Cosmc−-reactive serum IgM after tumor challenge (see online supplemental figure 2D), suggesting natural IgM may have contributed. Natural IgM reactivity with CMT93-Cosmc− tumor is partially blocked by free GalNAc. (A) Sera (diluted 1:10) from naïve WT and muMT mice were incubated with CMT93-Cosmc− cells followed by detection with goat anti-mouse IgM F(ab’)2 FITC and rat anti-mouse IgG-PE, with isotype background control subtracted for analysis of MFI (±SEM) (sera derived from: n=15 WT male mice and n=10 muMT male mice, with each data point representing a different mouse). Mouse IgM mAb was added to sera from muMT mice (10 µg/mL final) as an additional control. Results representative of two independent staining experiments performed with different sera. (B) Immunofluorescence staining of CMT93-Cosmc− tumor sections using VVL-fluorescein and rat anti-mouse IgM-BV421 (clone II/41). ImageJ was used to quantitate IgM signals (tumor sections were from five different WT, and three different muMT mice). (C) Flow cytometric analysis of IgM deposition on CMT93-Cosmc− tumor cells harvested from tumors grown in six WT and five muMT mice, with MFI (±SEM) indicated. Isotype control staining signal was subtracted as background. (D–E) Sera from 15 naïve WT mice and 10 muMT mice (spiked with mouse IgM mAb as in panel A) were incubated with glucose or GalNAc (5.5 mM final) prior to incubation with CMT93-Cosmc− or parental (E) cells, followed by detection with goat anti-mouse IgM F(ab’)2 FITC. MFI values for individual mice are shown. Two-tailed unpaired (A, C) and paired (D–E) Student’s t-tests were used to determine significance. P values are indicated above graphs. mAB, monoclonal antibody; MFI, mean fluorescence intensity; VVL, vicia villosa lectin; WT, wild-type. We examined the extent to which IgM recognized Tn using free GalNAc to block IgM recognition of its monosaccharide component. GalNAc blocking significantly reduced naïve serum IgM binding to CMT93-Cosmc− cells relative to glucose control blocking (figure 2D; 23±5% reduction, n=12 mice). The remaining non-Tn IgM binding may reflect additional natural antibody specificities, including reactivity to other tumor-associated or self-associated determinants. No change was observed in background binding with muMT sera spiked with irrelevant IgM control mAb (figure 2D). Further, GalNAc did not significantly block WT sera binding to parental CMT93 cells (figure 2E), consistent with minimal Tn antigen on parental CMT93. Thus, naïve WT mice exhibit IgM reactivity with CMT93-Cosmc− cells, a portion of which recognizes surface glycoproteins displaying GalNAc, that is, Tn. B-cell deficiency results in significantly increased CMT93-Cosmc− tumor growth Given the IgM present on CMT93-Cosmc− tumors in vivo, we investigated the impact of B-cell deficiency on tumor growth and found tumors grew more rapidly in muMT mice (figure 3A). We found decreased frequencies of CD45+ immune cells among tumor cell suspensions from muMT relative to WT mice (figure 3B). Among CD45+ cells, we observed significantly decreased Ly6C+Ly6G−CD11b+ monocytic myeloid-derived suppressor cells (Mo-MDSC) in muMT tumors (figure 3C). Ly6G+Ly6C−CD11b+ polymorphonuclear myeloid-derived suppressor cells (PMN-MDSC) comprised the greatest frequency among leukocytes in both WT and muMT mice but were not significantly different. B cells were present in WT, but not muMT tumors, and although T-cell frequencies among CD45+ leukocytes were not increased in WT tumors (figure 3D), programmed cell death protein 1 (PD-1) was expressed by a significantly higher frequency of tumor-infiltrating CD8+ T cells (figure 3E). This may suggest increased responsiveness of WT tumor-infiltrating T cells to tumor antigens, yet potential for exhaustion. Thus, B-cell deficiency was associated with increased CMT93-Cosmc− tumor growth and alterations in tumor-infiltrating leukocyte populations. CMT93-Cosmc− tumors grow more rapidly in B cell-deficient mice. WT and muMT mice were challenged s.c. with 4×106 CMT93-Cosmc− cells. (A) Tumor volumes and masses for tumors harvested from six WT and eight muMT mice. Asterisks (*) indicate significant differences (p<0.05). Results were repeated in an independent experiment. (B–E) Analysis of leukocyte frequencies in tumors (CD45+, B) and the distribution of myeloid cells (C), and lymphocytes (B220+ B cells; CD4+ and CD8+ T cells), (D) among CD45+ cells, and PD-1 expression on T cells (E) in tumor suspensions isolated from tumors from six WT and six muMT mice. Symbols in bar graphs indicate values for individual tumors, with p values indicated above graphs (unpaired two-tailed Student’s t-test). DC, dendritic cell; PD-1, programmed cell death protein 1; PMN, polymorphonuclear; s.c., subcutaneously; WT, wild-type. CMT93-Cosmc− tumors grow more rapidly and exhibit altered leukocyte infiltration in mice with a restricted B-cell receptor repertoire Previous studies have shown contradictory results for the effects of B-cell deficiency in tumor models grown in muMT mice.14 15 Therefore, we examined the importance of B cells and antibody production in CMT93-Cosmc− tumor growth using VHB1-8 transgenic (Tg) mice, which express a restricted B-cell receptor (BCR) repertoire due to fixed heavy chain expression.27 28 Subcutaneous CMT93-Cosmc− tumors grew more aggressively in VHB1-8Tg mice (figure 4A), and sera from naïve VHB1-8Tg mice showed minimal binding to CMT93-Cosmc− cells (figure 4B), despite only a 50% reduction in circulating IgM relative to WT controls (see online supplemental figure 3A). Recovered tumor cells also showed significantly reduced IgM and IgG deposition in VHB1-8Tg mice as assessed by flow cytometry (figure 4C) and immunofluorescence tissue staining (figure 4D). CMT93-Cosmc− tumors grow more rapidly in mice lacking a diverse BCR repertoire. (A) WT and VHB1-8Tg mice were challenged s.c. with 4×106 CMT93-Cosmc− cells, with tumor volumes and masses determined for tumors harvested from 11 WT and 9 VHB1-8 Tg mice. Results representative of two independent experiments. (B) Binding of serum IgM from naïve WT and VHB1-8Tg mice to CMT93-Cosmc− cells. muMT sera was used as a negative control. MFI (±SEM) is indicated (sera from 15 WT, 10 VHB1-8Tg, and 10 muMT male mice, with muMT sera spiked with 10 µg/mL mouse IgM mAb. Results representative of two independent staining experiments performed with different sera. (C) Flow cytometric analysis of IgM and IgG deposition on CMT93-Cosmc− tumor cells harvested from nine WT and seven VHB1-8Tg mice. Isotype control staining signal was subtracted as background. (D) Immunofluorescent staining of CMT93-Cosmc− tumor sections from WT and VHB1-8 Tg mice with rat anti-mouse IgM-PE. MFI (±SEM) analysis was done using ImageJ (tumor sections from five WT and five VHB1-8Tg mice). (E) Analysis of immune cells in tumor draining inguinal lymph nodes determined by flow cytometry. Pooled results from two independent experiments are shown for B and T-cell data (WT n=11 mice/group, VHB1-8 Tg n=10 mice/group). DC CD86 and MHC II expression and TFH data shown from one experiment (n=5 mice/group). (F–I) Analysis of frequencies of CD45+ leukocyte frequencies in tumors (F), along with myeloid cell (G) and lymphocyte (CD19+B220+ B cells; CD4+ and CD8+ T cells, and NK cells) (H) distribution among CD45+ cells, and frequencies of T cells expressing PD-1 (I) determined by flow cytometry (tumors from 10 WT and 10 VHB1-8Tg mice). An outlier was removed from the myeloid cell frequency analysis in G. Asterisks (*) indicate significant differences (p<0.05) (A) and symbols in bar graphs indicate values for individual tumors, with p values indicated above graphs (two-tailed unpaired Student’s t-test) (B–I). BCR, B-cell receptor; DC, dendritic cell; mAb, monoclonal antibody; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; NK, natural killer; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; s.c., subcutaneously; Tg, transgenic; WT, wild-type. DCs were modestly decreased in tumor draining lymph nodes (tdLN) of VHB1-8Tg mice (p=0.09), and these cells expressed significantly reduced major histocompatibility complex (MHC) class II (fivefold) and CD86 (twofold) expression relative to DCs in tdLN of WT mice (figure 4E; see gating shown in online supplemental figure 4A). Similar numbers of CD4+ and CD8+ T cells were found in VHB1-8Tg tdLN relative to WT mice. However, WT tdLN exhibited significantly increased IgG+, CD138+, and IgG+CD138+ antibody-secreting B cells, as well as interleukin (IL)-21-producing CD4+ (TFH) cells (figure 4E; see gating shown in online supplemental figure 4B), potentially indicating increased humoral responses to CMT93-Cosmc− tumors, consistent with results in figure 4C,D. In contrast to these differences observed in tdLN, inguinal LN from naïve VHB1-8Tg mice showed similar levels of MHC class II and only slightly reduced (25%) CD86 expression on DC (see online supplemental figure 3B). Although the numbers of plasmablasts were reduced ~threefold in naïve VHB1-8Tg LN relative to naïve WT LN, we noted the overall LN cellularity, including plasmablast numbers, was significantly increased in all tumor-bearing mice. Therefore, in the absence of a diverse BCR repertoire, tdLNs exhibited significantly reduced TFH, activated DCs, and plasmablasts, consistent with the reduced IgM and IgG reactivity with CMT93-Cosmc− cells in these mice (figure 4C,D). The frequency of CD45+ cells within CMT93-Cosmc− tumors was reduced in VHB1-8Tg mice relative to WT mice (figure 4F; see gating shown in online supplemental figure 4C,D). Among CD45+ leukocytes, VHB1-8Tg tumors had significantly increased Ly6G+Ly6C−CD11b+ PMN frequencies, and these cells had significantly increased programmed death-ligand 1 (PD-L1) expression (figure 4G)—a marker of suppression in the tumor microenvironment (TME).29 30 Differences were not observed in Ly6C+Ly6G−CD11b+ monocytes or CD11c+ DC; however, MHC class II expression was significantly decreased on DCs within VHB1-8Tg tumors (figure 4G), consistent with observations in the tdLN. CD4+, CD8+, natural killer (NK), and B-cell frequencies were significantly decreased in VHB1-8Tg relative to WT tumors (figure 4H). Furthermore, significantly fewer CD4+ and CD8+ TILs in VHB1-8Tg mice expressed PD-1 relative to WT mice (figure 4I). Similar to results with subcutaneous tumors in VHB1-8 Tg mice, we found orthotopic tumors, generated as a result of injection of CMT93-Cosmc− cells into the submucosal space of the rectum,31 grew more rapidly in VHB1-8Tg relative to WT mice (see online supplemental figure 3C). Moreover, despite similar CD45+ frequencies in WT versus VHB1-8Tg rectal tumors, we found skewing to TILs among leukocytes in WT mice, with significantly increased CD4+, CD8+ T, and B cells in rectal tumors from WT, relative to VHB1-8Tg mice (see online supplemental figure 3D). Thus, a restricted BCR repertoire results in significant alterations in tdLN responses, including reduced B-cell responses as well as DC activation, along with altered antitumor responses consisting of increased immunosuppressive MDSC, decreased DC activation potential and significantly decreased lymphocyte (B, T, and NK cells) presence in tumors. CMT93-Cosmc− tumors grow more rapidly and exhibit altered leukocyte infiltration in mice lacking natural antibody and IgM secretion To further investigate whether natural antibody production might be involved in the antitumor protection afforded by B cells, we assessed tumor growth in CD19−/− mice, which have significant defects in innate B cells and natural antibody production, including TACA-reactive IgM.20 32 33 Sera from naïve CD19−/− mice had little IgM reactivity with CMT93-Cosmc− cells (see online supplemental figure 5A) and tumors grew more aggressively with significantly increased masses observed at harvest (figure 5A). CMT93-Cosmc− tumors grow more rapidly in mice lacking natural IgM secretion. (A–B) WT and CD19−/− mice (A; WT n=8 mice, CD19−/− n=6 mice) and WT and μS−/− mice (B; WT n=10 mice, μS−/− n=9 mice) were challenged with 4×106 CMT93-Cosmc− cells subcutaneously (s.c.), with tumor volumes and masses recorded. (C) Flow cytometric analysis of IgM and IgG deposition on CMT93-Cosmc− tumor cells from WT n=10 and μS−/− n=9 mice; pooled from two independent experiments. (D) Immunofluorescence analysis of CMT93-Cosmc− tumor sections from WT n=5 and μS−/− n=6 mice with IgM mean fluorescense intensity (MFI)±SEM quantitation. (E) Flow cytometric analysis of immune cells in tdLN; B and T-cell data are pooled from two independent experiments (WT n=8, μS−/− n=9), and DC data are from one experiment (WT n=6, μS−/− n=5). (F–I) Flow cytometric analysis of CD45+ leukocyte frequencies in tumors (F), myeloid cell distribution (G), lymphocyte distribution among CD45+ cells (H), and PD-1+ T-cell frequencies (I). CD45+ and myeloid analyses used tumors from WT n=14 and μS−/− n=11 mice; lymphocyte analyses used WT n=10 and μS−/− n=8 mice. Symbols indicate individual tumors; p values are shown above graphs. Statistical comparisons were performed by two-tailed unpaired Student’s t-test. DC, dendritic cell; MFI, mean fluorescence intensity; MHC, major histocompatibility complex; PD-1, programmed cell death protein 1; PD-L1, programmed death-ligand 1; PMN, polymorphonuclear; s.c., subcutaneously, tdLN, tumor draining lymph nodes; WT, wild-type. We next investigated the role of secreted IgM in B cell-mediated protection using μS−/− mice, which express a normal B-cell repertoire and secrete class-switched antibodies. CMT93-Cosmc− tumors grew more rapidly in μS−/− mice (figure 5B). In addition to the lack of detectable IgM deposited on tumor cells from μS−/− mice (figure 5C,D), we found significantly reduced IgG deposition (figure 5C). As expected, no serum IgM binding to cultured CMT93-Cosmc− cells was detected for μS−/− mice (see online supplemental figure 5B). Thus, the inability to secrete IgM is associated with significantly increased CMT93-Cosmc− tumor growth along with reduced IgG deposition. In tdLN, similar overall numbers of B and T cells were found between μS−/− and WT mice; however, similar to VHB1-8Tg mice, TFH, IgG+, CD138+, and IgG+CD138+ antibody-secreting B cells were significantly decreased in μS−/− mice (figure 5E) suggesting a potential defect in humoral antitumor responses in the tdLN. TdLN showed reduced activation states of DCs, like VHB1-8Tg mice. These findings contrasted to results for inguinal lymph nodes from naïve mice whereby no differences were found between μS−/− and WT mice for DC activation state, TFH, or CD138+ and IgG+ B-cell numbers (see online supplemental figure 5C). Alterations in the TME of µS−/− mice also paralleled that observed for tumors grown in VHB1-8 Tg mice. The frequency of CD45+ cells within CMT93-Cosmc− tumors was reduced in μS−/− mice relative to WT mice (figure 5F) and tumors from μS−/− mice had significantly increased Ly6G+Ly6C−CD11b+ cells among CD45+ cells (figure 5G). These cells, as well as monocytic Ly6C+ cells, had significantly increased PD-L1 expression in μS−/− mice. Differences were not observed in Ly6C+ monocytic or DC frequencies; however, MHC class II expression was significantly decreased on DCs within tumors from μS−/− mice (figure 5G). CD4+, CD8+, NK, and B-cell frequencies among CD45+ cells were also significantly decreased in μS−/− tumors (figure 5H). Finally, as in muMT and VHB1-8Tg tumors, there was a significant decrease in the frequency of CD8+ TILs in μS−/− tumors that expressed PD-1 (figure 5I). Thus, deficiency in IgM secretion is associated with reduced B-cell responses in the tdLN as evidenced by reduced IgG-producing B cells and IgG deposition, along with reduced antitumor responses characterized by significantly increased immunosuppressive PMN-MDSC and Mo-MDSC, and significantly decreased DC activation and lymphocytes in the TME. Discussion Alterations in O-linked glycosylation are key features of adenocarcinomas, yet the immunologic consequences remain poorly understood. Using a newly generated Cosmc-deficient CMT93 colorectal tumor model, we identified a role for B cells and IgM in restraining the growth of Tn-antigen bearing solid tumors. Our study demonstrates (1) natural IgM antibodies bind with specificity to Tn-bearing tumors and (2) lack of tumor-reactive IgM is associated with increased Tn-bearing tumor growth, reduced B-cell responses in the draining lymph node, increased immunosuppressive MDSC, decreased DC activation potential, and decreased recruitment of B and T cells into tumors. Thus, IgM not only flags tumor cells for potential destruction and clearance but may reprogram the TME from an immunosuppressive myeloid phenotype towards an immunostimulatory environment. Our findings from tumor challenges in multiple mouse models of B-cell aberrations, including total deficiency, restricted repertoire, and defective natural IgM production and secretion, underscore the importance of B cells and IgM in the control of Tn-bearing tumors. MuMT mice have been used to study B cells in cancer for decades, with inconsistent findings now known to be attributed, in part, to microbiome alterations that dysregulate type-I interferon responses and enhanced effector T-cell activity.14 15 Tumors with high mutational burdens (TMB) and immunogenicity, including MC38, may reveal a limited role for B cells, whereas low TMB tumors, such as CMT93, may reveal a protective role.16 34 This possibility requires additional investigation. While regulatory B cells can inhibit antitumor responses, many studies support antitumor functions of B cells, including antigen presentation and antibody production.15 20 35 36 In this study, a diverse BCR repertoire along with IgM secretion was found to be important for the antitumor effects of B cells in the context of a solid Tn-expressing colorectal tumor. While the subcutaneous CMT93 model does not fully recapitulate the colorectal TME, it provides a tractable system to assess immune-mediated tumor control. The concordant findings in the orthotopic colorectal model strengthen the physiological relevance of BCR diversity and IgM in controlling Tn-expressing colorectal tumors. Although a previous study indicated a role for high levels of lymphoma-secreted IgM in promoting MDSC accumulation in a chronic lymphocytic leukemia model,37 other studies support antitumorigenic properties for IgM.13 38 39 Natural IgM produced by B-1 cells in response to TLR4/MD2 stimulation provides significant protection in liquid peritoneal carcinomatosis and leukemia models via pathways dependent on classical complement and inflammatory monocytes.20 21 Based on work with IghelMD4 transgenic mice, a diverse polyclonal B-cell repertoire was found to be critical for providing protection in mouse models of chemically-induced lung adenocarcinoma and lung lesions caused by intravenous injection of B16F10 melanoma cells, as was IgM for the clearance of cells displaying foreign neoantigens.22 The observed phenotypes are consistent with a role for natural IgM across models with distinct B-cell defects, increasing confidence that the effect is not solely attributable to impaired IgG responses or global B-cell deficiency. Nonetheless, we acknowledge that definitive proof of causality would require passive transfer of natural IgM into mice with B-cell deficits; however, such experiments are technically challenging due to the short half-life of IgM and thus, the need for high volumes of both WT and natural antibody-deficient control serum. There is increased interest in using IgM as a therapeutic modality for treatment of cancers and other diseases.39–41 The antitumor functions of IgM vary based on target recognition and may be multifaceted. Although pentameric IgM is approximately fivefold larger than IgG and considered less effective at extravasating and reaching tumor cells, a recent study demonstrated improved distribution and retention of IgM relative to IgG in inflamed and tumor tissues.42 Several IgM antibodies, including those targeting ganglioside Neu5GcGM3, surface proteins DR5 and GPC1, and GRP78, have shown encouraging preclinical and clinical trial results, with some inducing upwards of a 10,000-fold greater cytotoxic potency over IgG-agonists for the same target.13 39 IgM can activate lytic complement-dependent tumor cell killing,39 while non-lytic C3b/C4b recognition, C3a/C5a release, complement-independent pathways, IgM-dependent apoptotic signaling,38 and Fc receptors that bind IgM, including the polymeric Ig receptor, may also contribute.43 44 Tn is an oncofetal antigen due to its expression during embryonic development, and our work and that of others demonstrate the presence of Tn-reactive antibodies in the serum of healthy individuals. Tn-specific IgM, along with other glycan specificities, is present at birth, supporting conserved mechanisms exist to yield immunological surveillance against malignant cells.13 45 46 This, along with our finding that this IgM specificity is enriched in the B-1 pool of innate B cells35 and lacking in CD19−/− mice which are deficient in these self-reactive B cells20 supports that this self-specificity is part of the natural immune repertoire and plays a critical role in not only clearing transformed cells expressing altered glycans, but for priming more precise adaptive antitumor responses. Thus, our work supports a broader mechanism for IgM-mediated protection involving stimulation of the adaptive antitumor response. The initial characterization of the μS−/− mouse revealed a key role for IgM in promoting IgG responses to low doses of immunogenic antigens,47 48 and passive transfer of antigen-specific IgM together with antigen enhances humoral responses to other epitopes in some cases.49 The capacity for IgM to capture tumor antigens and render them immunogenic through immune complex formation presents another pathway by which natural IgM might promote antitumor responses. Our data support this possibility, as tumors from WT mice presented with significantly increased IgG deposition relative to µS−/− mice that lack IgM but not IgG secretion, and draining lymph nodes in µS−/− mice exhibited significantly reduced antibody-secreting cells, including IgG+ B cells. Because our flow cytometry did not capture fully differentiated IgG-secreting plasma cells in draining lymph node and bone marrow, we are likely underestimating differences in the IgG-secreting population in WT versus µS−/− mice. These findings, along with reduced activation of DC in both the tdLN and tumor, suggest IgM and/or IgG complexes containing tumor antigens may be more efficiently taken up by DCs and may also promote increased co-stimulatory potential. Decreased activated T cells and DCs in tumors from VHB1-8Tg and μS−/− mice, together with increased myeloid cells, including Ly6G+Ly6C−CD11b+ (PMN-MDSC), expressing higher levels of PD-L1, indicate a role for IgM in limiting the immunosuppressive potential of myeloid cells. The mechanisms by which B cells and IgM secretion contribute to these findings remain to be determined. In summary, our study highlights the importance of B cells and secreted IgM in constraining the growth of solid tumors bearing Tn antigen. The presence of Tn specificity within the natural IgM repertoire reveals an opportunity to improve surveillance and foster protection against adenocarcinomas. Further research examining the mechanisms by which tumor-reactive IgM carries out its antitumor effects will be essential for defining how these early humoral responses shape tumor-immune interactions. By delineating these pathways, our findings set the stage for a more complete understanding of how B cell-dependent mechanisms interface with innate and adaptive immunity to restrain the outgrowth of glycan-altered epithelial tumors. Methods Mice WT (RRID:IMSR_JAX:000664), muMT (B6.129S2-Ighmtm1Cgn/J; RRID:IMSR_JAX:002288), Rag1−/− (B6.129S7-Rag1tm1Mom/J; RRID:IMSR_JAX:002216) and homozygous VHB1-8 transgenic B1-8hi IgH knock-in (B6.129P2-Ptprca Ightm1Mnz/J; RRID:IMSR_JAX:007594) mice on a C57BL/6 background were purchased from the Jackson Laboratory. μS−/− mice (B6;129S4-Ighmtm1Che/J; RRID:IMSR_JAX:003751) were backcrossed eight times onto a C57BL/6 background. CD19−/− mice were as previously described.33 All mice were bred in-house in a specific pathogen-free (SPF) barrier facility. Mice used in experiments were sex (male) and age (8–12 weeks old) matched. Generation of CMT93-Cosmc− cells CMT93 cells (CCL-223; ATCC; RRID: CVCL_1986) were used. Origene’s CRISPR C1galt1c1 Mouse Gene Knockout Kit (KN302341, KN302341G1 Target Sequence 5’-GCAGATGGTGATGCTCATGG-3’, Donor Cassette KN302341D) was used according to the manufacturer’s instructions to knockout the Cosmc gene. 3 weeks post-selection, puromycin-resistant CMT93 cells were subcloned and assessed for high Tn expression using VVL (fluorescein). PCR was used to confirm the insert was present in the absence of puromycin (Fwd. Rev. Puromycin resistance gene insert, 5’-GGTGCATGACCCGCAAG-3’; Exon 2 Cosmc, 5’-GGGCGTGCAAGGAAGAA-3’). Protein expression in sonicated cell lysates (RIPA buffer+Halt Protease Inhibitor) was assessed by western blotting using Rabbit PolyAb C1galt1c1 (Proteintech, Cat.No.19254‐1‐AP) in conjunction with HRP-conjugated goat anti-rabbit IgG. Detection used SuperSignal West Femto ECL kit (Thermo Fisher). For GAPDH detection, membranes were stripped, reblocked, and reprobed with mouse anti-GAPDH (MilliporeSigma, clone 6C5, MAB734) in conjunction with HRP-conjugated goat anti-mouse IgG. ImageJ was used to detect band intensity. CMT93 and CMT93-Cosmc− cells were tested for Mycoplasma and rodent pathogens (IMPACT IV testing, IDEXX-RADIL) prior to expansion and aliquot freeze-down for use in mice. Tumor challenges CMT93 and CMT93-Cosmc− cells were expanded from master freeze-down stocks and grown in complete Roswell Park Memorial Institute medium (cRPMI) containing 10% fetal bovine serum (FBS), 1% penicillin/streptomycin, 1% L-glutamine, 1% sodium pyruvate, and 1% non-essential amino acid solution (NEAA). At 80% confluence, cells were trypsinized with 0.05% trypsin-EDTA and washed in phosphate-buffered saline (PBS) before injection. Mice were challenged subcutaneously in the right flank with 4×10⁶ cells in 100 µL PBS using a 27-gage needle under 2% isoflurane sedation. Once palpable, tumors were measured every 3 days beginning on day 11, and volume was estimated using the modified ellipsoidal formula: V=length×width²×π/6. In some experiments, tumors were injected into both flanks for additional characterization and optimal cutting temperature (OCT) embedding for downstream immunohistochemistry (IHC) analysis. Tumor-draining inguinal lymph nodes were pooled when tumors were grown bilaterally, with data presented on a per-lymph-node basis. Tumor measurements were obtained by two individuals, one blinded to measure tagged mice and one to randomize cage selection and record measurements. Exclusion criteria included oozing ulcerated tumors before the experimental endpoint. Tumor growth kinetics varied between independent experiments, likely due to technical differences in large-scale preparation and injection of adherent tumor cells, including cell viability at injection and time between harvest and injection. Therefore, statistical comparisons and conclusions were restricted to genotype-matched groups analyzed within the same experiment. For orthotopic rectal tumor implantation, as described in Kasashima et al,31 6×105 cells were injected in a 20 µL volume into the submucosal layer of the rectum. Flow cytometry CMT93 and CMT93-Cosmc− cells were trypsinized, washed, resuspended in RPMI containing 2% newborn calf serum (NBCS) (Gibco), and stained with fluorochrome-conjugated lectins specific for T antigen (PNA Alexa Fluor 568) and Tn antigen (VVL Fluorescein; Vector Labs) at 1 µg/mL or with mouse sera diluted 1:10. To assess sialylation, 3×10⁵ CMT93-Cosmc− cells were treated with 10 mU Arthrobacter ureafaciens neuraminidase (New England Biolabs) for 1 hour, washed in PBS/2% NBCS, and stained for 25 min. Sialic acid residues were detected using B72.3 (Thermo Scientific). For GalNAc blocking, sera were preincubated with free GalNAc or glucose in PBS for 30 min before incubation with 1×10⁵ CMT93-Cosmc− cells in RPMI containing 5.5 mM GalNAc or glucose. Mouse IgM Abs (anti-TNP, G155-228, and anti-NP, 3A11) were added to muMT sera as negative controls. IgM reactivity was detected using fluorochrome-conjugated goat anti-mouse IgM F(ab’)2 (Southern Biotechnology Associates). For staining single-cell tumor suspensions, tumors were minced and digested for 45 min at 37°C/5% CO₂ in RPMI containing 2% fetal calf serum (FCS), 10 U/mL DNase I (Sigma), and 200 µg/mL type IV collagenase (Worthington). Filtered tumor suspensions were stained with fluorochrome-labeled antibodies against CD45, CD11b, Ly6G, Ly6C, CD11c, CD19, B220, CD138, IgG, IgM, CD4, CD8, DX5, NK1.1, CD86, PD-L1, CXCR5, PD1, and MHC class II (I-Ad/I-Ed), obtained from BD Biosciences, eBioscience, and BioLegend. Fc block (BioLegend), Live/Dead viability dye (Invitrogen), and CountBright beads were included. Tumor-draining inguinal lymph nodes were dissociated and stained similarly. Fluorochrome-labeled isotype controls were used to determine background staining. For detection of IL-21-producing T follicular helper cells, cells were stimulated with phorbol 12-myristate 13-acetate (PMA) (30 ng/mL) and ionomycin (1 µM) for 5 hours at 37°C/5% CO₂ in cRPMI+10% FCS, with GolgiStop and GolgiPlug added after 1 hour. Cells were stained with antibodies against CD4, PD-1, and Live/Dead viability dye, fixed/permeabilized overnight at 4°C using Foxp3 Fix/Perm buffer (eBioscience), washed, and intracellularly stained with PE-labeled IL-21 (FFA21) or rat IgG2a isotype control mAb. Single-cell tumor and lymph node suspensions were fixed in 1.5% buffered formaldehyde and analyzed on a Fortessa X-20 cytometer (BD Biosciences) with FSC-A/FSC-H (forward scatter area/forward scatter height) doublet exclusion. Data were analyzed using FlowJo software (TreeStar, V.10; RRID:SCR_008520). CD45+ immune cells were quantified as a percentage of total viable cells recovered from each tumor, reflecting relative immune composition of the TME rather than total tumor cellularity. Immunofluorescence analysis of tumor tissue sections Tumors were embedded in OCT and frozen at −80°C. Tissue sections (5 µm) on poly-L-lysine-coated slides were fixed in cold acetone, rinsed, and blocked in PBS/2% bovine serum albumin (BSA). Sections were stained in PBS/2% BSA with fluorochrome-conjugated VVL, PNA, or mouse anti-mouse IgM. Fluorochrome-labeled isotype controls were used to determine background staining. Sections were mounted with Fluoromount-G, dried overnight, imaged, and analyzed using ImageJ (V.1.54g; RRID:SCR_003070) to determine fluorescence intensity. Statistical analyses Data are shown as means±SEM with individual data points. Differences between sample means were assessed using unpaired or paired Student’s t-tests, as indicated in the figure legends. Analyses were performed using GraphPad Prism V.10 (RRID:SCR_002798). Supplementary material